Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Longeveron Inc. - Class A Common stock (NQ:LGVN)

1.420 -0.050 (-3.40%)
Streaming Delayed Price Updated: 11:59 AM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
3 Penny Stocks That Could Rise 500% in 2023
Tilt the odds in your favor in 2023 with some of these high-potential penny stocks. The risks are high, but so are the rewards. 
Via InvestorPlace
Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug
Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi.  
Via Benzinga
Elon Musk Is a Genius Market Timer. That’s Bad News for Tesla (TSLA) Stock.
Elon Musk is great at timing the market. He's selling TSLA stock now, and savvy investors would be wise to follow suit. 
Via InvestorPlace
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket
Gainers Netcapital Inc. (NASDAQ: NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million. 
Via Benzinga
Longeveron: Q2 Earnings Insights
  Longeveron (NASDAQ:LGVN) reported its Q2 earnings results on Friday, August 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
How to Find Stocks That Rise 10x
Investors looking for 10X stocks should prioritize companies in high-growth areas that demonstrate high earnings quality. 
Via InvestorPlace
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market
Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 80.8% to $8.5 during Wednesday's pre-market session. The company's market cap stands at $344.2 million. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning. 
Via InvestorPlace
Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket
Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday. 
Via Benzinga
Longeveron's Return On Capital Employed Insights
Longeveron (NASDAQ:LGVN) brought in sales totaling $466 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 60.23%, resulting in a loss of $5.62 million. 
Via Benzinga
PFE, MRNA Stocks: What to Know as the FDA Approves New Booster Shots
Pfizer (PFE) and Moderna (MRNA) stocks are in the news Wednesday as the FDA approves new booster shots for the Covid-19 Omicron variant. 
Via InvestorPlace
Why Is Longeveron (LGVN) Stock on the Move Today?
Longeveron (LGVN) stock is on the move Wednesday after the FDA granted its fast-track designation for heart treatment Lomecel-B. 
Via InvestorPlace
Longeveron Shares Ascend As FDA Grants Fast Track Status To Congenital Heart Disease Candidate
Longeveron (NASDAQ: LGVN) received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead drug Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS). 
Via Benzinga
EXCLUSIVE: Longeveron's Lomecel-B Product Gets US FDA Fast Track Designation For Treatment Of Hypoplastic Left Heart Syndrome in Infants
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Longeveron Inc (NASDAQ: LGVN) Lomecel-B for the treatment of Hypoplastic Left Heart... 
Via Benzinga
European Patent Office Issues Intent To Grant Longeveron Patent Related To Methods To Monitor Efficacy Of Lomecel-B™ Cell Therapy
Longeveron Inc. (NASDAQ: LGVN) announced that the European Patent Office (EPO) had issued a notice of its intent to grant the Company a patent (EP Application No. 
Via Benzinga
EXCLUSIVE: Longeveron's Heart Disease Cell Therapy Poised To Secure European Patent
The European Patent Office has issued a notice of its intent to grant Longeveron Inc (NASDAQ: LGVN) a patent related to methods to treat endothelial dysfunction and monitor the efficacy of allogeneic... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Earnings Scheduled For August 12, 2022
Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million. 
Via Benzinga
Longeveron Earnings Preview
  Longeveron (NASDAQ:LGVN) is set to give its latest quarterly earnings report on Friday, 2022-08-12. Here's what investors need to know before the announcement. Analysts estimate that Longeveron will... 
Via Benzinga
Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry?
According to Grand View Research, the global cell therapy market was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% between 2021 and 2028. 
Via Benzinga
Publication Of Peer-Reviewed Study In Journal Of The Alzheimer's Association Could Mark A Significant Step For Longeveron
Recent publishing of Longeveron Inc.’s (NASDAQ: LGVN) 
Via Benzinga
Aging Veterans May Have New Options As VA And Longeveron Make Progress On Clinical Research Of Aging Frailty Treatment
The U.S. Department of Veterans Affairs (VA) partnered with Longeveron Inc. (NASDAQ: LGVN) to explore the clinical-stage biotech’s novel cell therapies as a potential treatment for aging frailty. 
Via Benzinga
7 Moonshot Investments Upending a $10 Trillion Industry
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday
Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market. 
Via Benzinga
Why U.S. Stocks Are Trading Higher After Rise In Jobless Claims
U.S. stocks traded higher this morning, following the release of data on initial jobless claims. 
Via Benzinga
This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session
Gainers United Maritime Corporation (NASDAQ: USEA) jumped 180.4% to $8.02. The company’s stock jumped 190% on Wednesday after completing its spin-off from Seanergy Maritime Holdings Corp. 
Via Benzinga
7 Ways to Prepare for a Recession: An Investor’s Guide
There are plenty of ways to prepare for a recession. Here are seven ways you can make sure you're ready for whatever comes next. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.